The clinical triumph of anti–PD-1/PD-L1 therapy is largely ascribed to its ability to reinvigorate tumor antigen–specific T cells that have been rendered inactive by the interaction of PD-1 on T cells with its ligand PD-L1 on tumor cells (12). The gene discussed is CD274; the disease is neoplasm.